{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resectable+Astrocytoma", "query": { "condition": "Resectable Astrocytoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resectable+Astrocytoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T13:43:30.569Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522820" }, { "nct_id": "NCT00041587", "title": "Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Glioma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Mixed Oligoastrocytoma" ], "interventions": [ { "name": "IL13-PE38QQR", "type": "DRUG" }, { "name": "targeted fusion protein therapy", "type": "PROCEDURE" }, { "name": "surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2002-07", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2011-06-06", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 2, "location_summary": "Denver, Colorado • Cleveland, Ohio", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00041587" }, { "nct_id": "NCT07089641", "title": "ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "IDH Wildtype Glioblastoma", "Recurrent Astrocytoma", "IDH Wildtype Recurrent Glioblastoma", "Resectable Astrocytoma", "Resectable Glioblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "EGFR Inhibitor ERAS-801", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-07-28", "completion_date": "2028-07-30", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07089641" }, { "nct_id": "NCT00003461", "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors", "Metastatic Cancer", "Neuroblastoma" ], "interventions": [ { "name": "surgical procedure", "type": "PROCEDURE" }, { "name": "astatine At 211 monoclonal antibody 81C6", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-02", "completion_date": "2005-02", "has_results": false, "last_update_posted_date": "2014-08-21", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003461" }, { "nct_id": "NCT06090903", "title": "Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma", "Resectable Glioblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Medical Chart Review", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-04-14", "completion_date": "2028-04-18", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06090903" }, { "nct_id": "NCT02722512", "title": "Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Astrocytoma, Grade III", "Anaplastic Ependymoma", "Clear Cell Ependymoma", "Ependymoma" ], "interventions": [ { "name": "Heat Shock Protein Peptide Complex-96 (HSPPC-96)", "type": "BIOLOGICAL" }, { "name": "Tumor Resection", "type": "PROCEDURE" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 10, "start_date": "2016-07", "completion_date": "2019-11-13", "has_results": false, "last_update_posted_date": "2025-02-18", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722512" }, { "nct_id": "NCT00979173", "title": "Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "AC480", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Annick Desjardins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2009-11", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2014-01-29", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00979173" }, { "nct_id": "NCT04003649", "title": "IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma", "Refractory Glioblastoma" ], "interventions": [ { "name": "IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-12-02", "completion_date": "2026-09-26", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003649" }, { "nct_id": "NCT00003484", "title": "Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neuroblastoma" ], "interventions": [ { "name": "carmustine", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "surgical procedure", "type": "PROCEDURE" }, { "name": "iodine I 131 monoclonal antibody 81C6", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Darell D. Bigner, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "1997-09", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2015-04-23", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003484" }, { "nct_id": "NCT00814593", "title": "Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "lymphokine-activated killer cells", "type": "BIOLOGICAL" }, { "name": "polifeprosan 20 with carmustine implant", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Lisata Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2008-11", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2019-05-10", "last_synced_at": "2026-06-25T13:43:30.569Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00814593" } ] }